MinervaX Announces Completion of 47.4 mEUR Financing [Back Bay Transaction]

Our investment bankers and strategy team are proud to serve as long-time advisors to MinervaX and congratulate the team for their recent $57 Million Series B raise to accelerate the development of its vaccine for novel Group B Streptococcus.